Zydus injectable facility in Vadodara gets U.S. FDA inspection report with VAI status

The U.S. Food and Drug Administration has issued an establishment inspection report (EIR) with a voluntary action indicated (VAI) classification to an injectable facility of Zydus Lifesciences in Vadodara.

The company received the EIR for a GMP follow-up inspection the U.S. FDA conducted at the facility in Jarod, Vadodara, from August 25 to September 5, 2025 classifying the unit as VAI. The inspection followed a warning letter issued on August 29, 2024 by the U.S. FDA, the company said.